ORIFARM GENERICS A/S - CVR: 25674030

2022, DKK

07.06.2023

Bruttoresultat

261''

Primær drift

69.553'

Årets resultat

54.462'

Aktiver

1.345''

Kortfristede aktiver

1.298''

Egenkapital

432''

Afkastningsgrad

5 %

Soliditetsgrad

32 %

Likviditetsgrad

144 %

Resultat

07.06.2023

Årsrapport	2022 07.06.2023	2021 05.07.2022	2020 14.06.2021	2019 25.06.2020	2018 31.05.2019	2017 31.05.2018	2016 31.05.2017	2015 03.06.2016
Nettoomsætning	2.074.832.000	1.757.348.000	688.426.000	545.016.000	504.442.000
Bruttoresultat	261.488.000	329.329.000	274.178.000	197.046.000	162.693.000	0	0	40.010.000
Resultat af primær drift	69.553.000	180.648.000	185.611.000	134.228.000	92.584.000	101.789.000	107.630.000	970.000
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0	0	0	0
Finansielle indtægter	40.687.000	21.820.000	6.643.000	2.516.000	2.253.000	1.389.000	2.581.000	249.000
Finansieringsomkostninger	0	0	0	0	0	0	0	-251.000
Andre finansielle omkostninger	-40.706.000	-11.719.000	-5.567.000	-3.407.000	-4.885.000	-4.327.000	-3.251.000	0
Resultat før skat	69.534.000	190.749.000	186.687.000	133.337.000	89.952.000	98.851.000	106.960.000	968.000
Resultat	54.462.000	150.140.000	145.514.000	103.855.000	70.055.000	76.351.000	83.250.000	605.000
Forslag til udbytte	0	-150.000.000	-10.000.000	0	0	0	0	0

Aktiver

07.06.2023

Årsrapport	2022 07.06.2023	2021 05.07.2022	2020 14.06.2021	2019 25.06.2020	2018 31.05.2019	2017 31.05.2018	2016 31.05.2017	2015 03.06.2016
Kortfristede varebeholdninger	546.606.000	434.112.000	232.055.000	163.920.000	150.602.000	152.484.000	124.509.000	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	748.459.000	675.945.000	176.945.000	118.524.000	102.324.000	68.702.000	55.759.000	41.177.000
Likvider	2.791.000	16.240.000	0	0	0	4.182.000	25.451.000	0
Kortfristede aktiver	1.297.856.000	1.126.297.000	409.000.000	282.444.000	252.926.000	225.368.000	205.719.000	41.177.000
Immaterielle aktiver og goodwill	47.171.000	45.829.000	46.784.000	47.752.000	42.091.000	34.320.000	34.888.000	5.278.000
Finansielle anlægsaktiver	0	0	0	0	0	0	0	0
Materielle aktiver	152.000	0	0	0	0	0	0	0
Langfristede aktiver	47.323.000	45.829.000	46.784.000	47.752.000	42.091.000	34.320.000	34.888.000	5.278.000
Aktiver	1.345.179.000	1.172.126.000	455.784.000	330.196.000	295.017.000	259.688.000	240.607.000	46.455.000

Aktiver

07.06.2023

Passiver

07.06.2023

Årsrapport	2022 07.06.2023	2021 05.07.2022	2020 14.06.2021	2019 25.06.2020	2018 31.05.2019	2017 31.05.2018	2016 31.05.2017	2015 03.06.2016
Forslag til udbytte	0	150.000.000	10.000.000	0	0	0	0	0
Egenkapital	431.719.000	527.257.000	201.194.000	145.680.000	116.825.000	86.770.000	60.420.000	8.038.000
Hensatte forpligtelser	10.430.000	10.204.000	10.373.000	10.469.000	8.953.000	6.854.000	6.728.000	1.161.000
Langfristet gæld til banker	0	0	0	0	0	0	0	0
Anden langfristet gæld	0	0	0	0	0	0	0	0
Leverandører af varer og tjenesteydelser	218.264.000	298.449.000	96.376.000	69.269.000	35.078.000	34.883.000	34.143.000	2.032.000
Kortfristede forpligtelser	903.030.000	634.665.000	236.868.000	171.867.000	169.239.000	166.064.000	173.459.000	37.256.000
Gældsforpligtelser	903.030.000	634.665.000	244.217.000	174.047.000	169.239.000	166.064.000	173.459.000	37.256.000
Forpligtelser	903.030.000	634.665.000	244.217.000	174.047.000	169.239.000	166.064.000	173.459.000	37.256.000
Passiver	1.345.179.000	1.172.126.000	455.784.000	330.196.000	295.017.000	259.688.000	240.607.000	46.455.000

Passiver

07.06.2023

Nøgletal

07.06.2023

Årsrapport	2022 07.06.2023	2021 05.07.2022	2020 14.06.2021	2019 25.06.2020	2018 31.05.2019	2017 31.05.2018	2016 31.05.2017	2015 03.06.2016
Afkastningsgrad	5,2 %	15,4 %	40,7 %	40,7 %	31,4 %	39,2 %	44,7 %	2,1 %
Dækningsgrad	12,6 %	18,7 %	39,8 %	36,2 %	32,3 %	Na.	Na.	Na.
Resultatgrad	2,6 %	8,5 %	21,1 %	19,1 %	13,9 %	Na.	Na.	Na.
Varelagerets omsætningshastighed	3,8	4,0	3,0	3,3	3,3	Na.	Na.	Na.
Egenkapitals-forretning	12,6 %	28,5 %	72,3 %	71,3 %	60,0 %	88,0 %	137,8 %	7,5 %
Payout-ratio	Na.	99,9 %	6,9 %	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	Na.	Na.	Na.	Na.	Na.	Na.	Na.	386,5 %
Soliditestgrad	32,1 %	45,0 %	44,1 %	44,1 %	39,6 %	33,4 %	25,1 %	17,3 %
Likviditetsgrad	143,7 %	177,5 %	172,7 %	164,3 %	149,4 %	135,7 %	118,6 %	110,5 %

Resultat

07.06.2023

Gæld

07.06.2023

Årsrapport

07.06.2023

Nyeste:01.01.2022- 31.12.2022(offentliggjort: 07.06.2023)

Information om virksomhedens regnskabsklasse:This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (large). The accounting policies applied to these financial statements are consistent with those applied last year.

Oplysning om pantsætninger og sikkerhedsstillelser:16 Assets charged and collateralThe entity has provided guarantees under which the guarantors assume joint and several liability for Group enterprises’ net debt with bank and credit institution. The Group’s total net debt in relation to this guarantee is booked at MDKK 4,831 at 31.12.2022. The Entity has normal trade obligations on returned goods, and no significant losses are expected.

Beretning

07.06.2023

Dato for ledelsens godkendelse af årsrapporten:2023-06-05

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:The Board of Directors and the Executive Board have today considered and approved the annual report of Orifarm Generics A/S for the financial year 01. 01. 2022 - 31. 12. 2022.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Primary activitiesOrifarm Generics A/S is part of Orifarm Group which is a dynamic international player in the healthcare business. Orifarm Generics A/S is manufacturing and selling generics pharmaceuticals within Orifarm Healthcare portfolio. Orifarm Healthcare portfolio is structured in four Strategic Business Areas and include strong brands within OTC, Consumer Healthcare and Specialty Pharma (Rx). In addition, a diverse portfolio of Niche Generics. The Healthcare Portfolio operates across growing Health Areas such as Cough & Cold, Vitamins & Food Supplements, Immune Boost, Gastro, Allergy and Mood. Further, the portfolio supports many patients across the different stage of illness from prevention to alleviation of symptoms to treatment. High-quality medication at affordable prices and access to patients is of highest priority to Orifarm and the Healthcare Portfolio is available in pharmacies (physical outlets and online pharmacies), primary care and in some markets retail and drug stores.